Q-Line Biotech Ltd (QLINE) share fundamentals
Q-Line Biotech Ltd is a small-cap company in Health Care (Biotechnology) with a market capitalisation of ₹1,230 crore. Here is where it stands on valuation, profitability, debt and growth as of 5 November 2026, and how it compares with the median Health Care company.
Financial health score
Out of 100, across five pillars of reported fundamentals.
What stands out
- Strong ROCE at 26.4%
- ROE 25.5%
- Negative free cash flow
Q-Line Biotech Ltd vs the Health Care median
| Metric | QLINE | Sector median | |
|---|---|---|---|
| PE ratioprice paid for each rupee of yearly profit | 21.77x | 26.11x | Better |
| Price to bookprice against the book value of assets | 4.99x | 2.93x | Weaker |
| EV / EBITDAbusiness value against operating profit | 13.41x | 18.12x | Better |
| Dividend yieldyearly dividend as a share of price | — | 0.4% | |
| Return on equityprofit on shareholders’ money | 25.5% | 10.6% | Better |
| ROCEprofit on all capital employed | 26.4% | 12.7% | Better |
| Net profit marginprofit kept from each rupee of sales | 16% | 7.7% | Better |
| Debt to equityborrowing against shareholders’ money | 0.92x | 0.2x | Weaker |
| Interest coveragehow many times profit covers interest | 4.73x | 7.86x | Weaker |
| Current ratioshort-term assets against short-term dues | 1.64x | 1.95x | Weaker |
| Revenue growth (1Y)change in sales over a year | 7.9% | 13.9% | Weaker |
| EPS growth (1Y)change in earnings per share over a year | 56.9% | 8% | Better |
| Promoter holdingshare owned by the founders or parent | 67.5% | 56.7% | Better |
| Promoter pledgepromoter shares pledged as loan security | 0% | 0% | In line |
| Betahow much it moves with the market | — | 0.88 | |
| 1-year returnshare price change over 52 weeks | 12.9% | -0.6% |
Tell DecideChart your amount, timeline and target return, and AI builds a full A4 report with risks, scenarios and worst cases. Your first report is free.
Other Health Care companies
Sun Pharmaceutical Industries LimitedSUNPHARMA · score 77.8
Divi's Laboratories LtdDIVISLAB · score 76
Torrent Pharmaceuticals LtdTORNTPHARM · score 63.7
Laurus Labs LtdLAURUSLABS · score 67.5
Apollo Hospitals Enterprise LimitedAPOLLOHOSP · score 59.5
Zydus Lifesciences LtdZYDUSLIFE · score 80
Dr. Reddy's Laboratories LimitedDRREDDY · score 67.9
Cipla LtdCIPLA · score 68.1
Mankind Pharma LtdMANKIND · score 57.4
Aurobindo Pharma LimitedAUROPHARMA · score 73.4
Lupin LimitedLUPIN · score 91.9
Max Healthcare Institute LimitedMAXHEALTH · score 59.9Frequently asked questions
What is the PE ratio of Q-Line Biotech Ltd?
Q-Line Biotech Ltd trades at a PE of 21.77x as of 5 November 2026, against a Health Care median of 26.11x. PE is the price paid for each rupee of yearly profit.
Is Q-Line Biotech Ltd debt free?
No. Q-Line Biotech Ltd has a debt-to-equity ratio of 0.92x, against a Health Care median of 0.2x.
What is the ROCE and ROE of Q-Line Biotech Ltd?
Q-Line Biotech Ltd has a return on capital employed of 26.4% and a return on equity of 25.5%. The Health Care medians are 12.7% and 10.6%.
What is the DecideChart health score of Q-Line Biotech Ltd?
Q-Line Biotech Ltd scores 79.5 out of 100, graded Healthy. The score weighs profitability, debt, valuation, growth and governance from the company’s reported numbers. It is a research aid, not a recommendation.
Should I buy Q-Line Biotech Ltd shares?
DecideChart does not give buy or sell tips and is not linked to SEBI, BSE or NSE. Use these numbers for your own research, compare Q-Line Biotech Ltd with its Health Care peers, and consult a SEBI-registered adviser before investing.
Fundamentals from a public market-data screener, as of 5 November 2026. Figures can lag company filings. DecideChart is AI-based, not linked to SEBI, BSE or NSE, and does not give investment advice.